Top

Published in:

01-05-2015 | Vascular Biology (T Hla, Section Editor)

Sphingosine-1-Phosphate Receptor Subtype 2 Signaling in Endothelial Senescence-Associated Functional Impairments and Inflammation

Authors: Jiawei Zhao, Dante Garcia, Allison Gartung, Menq-Jer Lee

Published in: Current Atherosclerosis Reports | Issue 5/2015

Abstract

Endothelial inflammation is an important risk factor in the initiation and development of vascular disease. Therefore, signaling cascades and patho-physiological outcomes of endothelial inflammation are important questions in vascular biology. Recent studies suggest that sphingosine-1-phosphate receptor subtype 2 (S1PR2) signaling in endothelial cells (ECs) play a critical role in endothelial inflammation. For example, ECs present in atherosclerotic plaques exhibit senescence phenotype. Levels of S1PR2 are markedly increased in cultured senescent ECs and in lesion regions of atherosclerotic endothelium. Also, inflammatory cytokines and mechanical flow stress profoundly increase S1PR2 levels in ECs. Inhibition of endothelial S1PR2 signaling diminishes endothelial senescence-associated functional impairments and atherogenic stimuli-induced endothelial activation. In contrast, activation of endothelial S1PR2 stimulates the production of pro-inflammatory chemokines/cytokines and lipid mediators in ECs. In this article, we will review signaling and functions of sphingosine-1-phosphate (S1P) receptors in endothelial biology, with particular focus on endothelial S1PR2 signaling-mediated endothelial inflammation.

Spiegel S, Milstien S. Sphingosine-1-phosphate: signaling inside and out. FEBS Lett. 2000;476(1–2):55–7.CrossRefPubMed

Moolenaar WH, van Meeteren LA, Giepmans BN. The ins and outs of lysophosphatidic acid signaling. Bioessays. 2004;26(8):870–81. doi:10.1002/bies.20081.CrossRefPubMed

Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, et al. Sphingosine-1-phosphate as a ligand for the G protein coupled receptor EDG-1. Science. 1998;279(5356):1552–5.CrossRefPubMed

An S, Bleu T, Huang W, Hallmark OG, Coughlin SR, Goetzl EJ. Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids. FEBS Lett. 1997;417(3):279–82.CrossRefPubMed

Zondag GC, Postma FR, Etten IV, Verlaan I, Moolenaar WH. Sphingosine 1-phosphate signalling through the G-protein-coupled receptor Edg-1. Biochem J. 1998;330(2):605–9.PubMedCentralPubMed

Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296(5566):346–9. doi:10.1126/science.1070238.CrossRefPubMed

Spiegel S. Sphingosine 1-phosphate: a prototype of a new class of second messengers. J Leukoc Biol. 1999;65(3):341–4.PubMed

Moolenaar WH. Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res. 1999;253(1):230–8.CrossRefPubMed

Igarashi Y, Yatomi Y. Sphingosine 1-phosphate is a blood constituent released from activated platelets, possibly playing a variety of physiological and pathophysiological roles. Acta Biochim Pol. 1998;45(2):299–309.PubMed

10.

Hla T, Lee MJ, Ancellin N, Liu CH, Thangada S, Thompson BD, et al. Sphingosine-1-phosphate: extracellular mediator or intracellular second messenger? Biochem Pharmacol. 1999;58(2):201–7.CrossRefPubMed

11.

Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 2009;325(5945):1254–7. doi:10.1126/science.1176709.CrossRefPubMedCentralPubMed

12.

Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010;465(7301):1084–8. doi:10.1038/nature09128.CrossRefPubMedCentralPubMed

13.

An SZ, Goetz EJ, Lee HY. Signaling mechanisms and molecular characteristics of G protein-coupled receptors for lysophosphatidic acid and sphingosine 1-phosphate. J Cell Biochem. 1998;147–57.

14.

Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, et al. International union of pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2002;54(2):265–9.CrossRefPubMed

15.

Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell. 1999;99(3):301–12.CrossRefPubMed

16.

Estrada R, Zeng Q, Lu H, Sarojini H, Lee JF, Mathis SP, et al. Up-regulating sphingosine 1-phosphate receptor-2 signaling impairs chemotactic, wound-healing, and morphogenetic responses in senescent endothelial cells. J Biol Chem. 2008;283(44):30363–75. doi:10.1074/jbc.M804392200.CrossRefPubMedCentralPubMed

17.

Eskan MA, Rose BG, Benakanakere MR, Lee MJ, Kinane DF. Sphingosine 1-phosphate 1 and TLR4 mediate IFN-beta expression in human gingival epithelial cells. J Immunol. 2008;180(3):1818–25.CrossRefPubMed

18.

Hsu A, Zhang W, Lee JF, An J, Ekambaram P, Liu J, et al. Sphingosine-1-phosphate receptor-3 signaling up-regulates epidermal growth factor receptor and enhances epidermal growth factor receptor-mediated carcinogenic activities in cultured lung adenocarcinoma cells. Int J Oncol. 2012;40(5):1619–26. doi:10.3892/ijo.2012.1379.PubMedCentralPubMed

19.•

Zhang W, Zhao J, Lee JF, Gartung A, Jawadi H, Lambiv WL, et al. ETS-1-mediated transcriptional up-regulation of CD44 is required for sphingosine-1-phosphate receptor subtype 3-stimulated chemotaxis. J Biol Chem. 2013;288(45):32126–37. doi:10.1074/jbc.M113.495218. This study characterized a novel ETS-1/CD44 pathway in S1P-stimulated chemotaxis.CrossRefPubMedCentralPubMed

20.

Lee MJ, Thangada S, Paik JH, Sapkota GP, Ancellin N, Chae SS, et al. Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis. Mol Cell. 2001;8(3):693–704.CrossRefPubMed

21.

Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest. 2000;106(8):951–61. doi:10.1172/jci10905.CrossRefPubMedCentralPubMed

22.

Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest. 2001;108(5):689–701. doi:10.1172/jci12450.CrossRefPubMedCentralPubMed

23.•

Zhang W, An J, Jawadi H, Siow DL, Lee JF, Zhao J, et al. Sphingosine-1-phosphate receptor-2 mediated NFkappaB activation contributes to tumor necrosis factor-alpha induced VCAM-1 and ICAM-1 expression in endothelial cells. Prostaglandins Other Lipid Mediat. 2013;106:62–71. doi:10.1016/j.prostaglandins.2013.06.001. S1PR2 plays a key role in endothelial inflammation.CrossRefPubMed

24.

Van Brocklyn JR, Lee MJ, Menzeleev R, Olivera A, Edsall L, Cuvillier O, et al. Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. J Cell Biol. 1998;142(1):229–40.CrossRefPubMedCentralPubMed

25.

Lee MJ, Evans M, Hla T. The inducible G protein-coupled receptor edg-1 signals via the G(i)/mitogen-activated protein kinase pathway. J Biol Chem. 1996;271(19):11272–9.CrossRefPubMed

26.

Hla T, Maciag T. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J Biol Chem. 1990;265(16):9308–13.PubMed

27.

Liu F, Verin AD, Wang P, Day R, Wersto RP, Chrest FJ, et al. Differential regulation of sphingosine-1-phosphate- and VEGF-induced endothelial cell chemotaxis. Involvement of G(ialpha2)-linked Rho kinase activity. Am J Respir Cell Mol Biol. 2001;24(6):711–9.CrossRefPubMed

28.

Paik JH, Chae S, Lee MJ, Thangada S, Hla T. Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha vbeta3- and beta1-containing integrins. J Biol Chem. 2001;276(15):11830–7. doi:10.1074/jbc.M009422200.CrossRefPubMed

29.

Morales-Ruiz M, Lee MJ, Zollner S, Gratton JP, Scotland R, Shiojima I, et al. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem. 2001;276(22):19672–7. doi:10.1074/jbc.M009993200.CrossRefPubMed

30.

Lee JF, Zeng Q, Ozaki H, Wang L, Hand AR, Hla T, et al. Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. J Biol Chem. 2006;281(39):29190–200. doi:10.1074/jbc.M604310200.CrossRefPubMed

31.

Lee JF, Ozaki H, Zhan X, Wang E, Hla T, Lee MJ. Sphingosine-1-phosphate signaling regulates lamellipodia localization of cortactin complexes in endothelial cells. Histochem Cell Biol. 2006;126(3):297–304. doi:10.1007/s00418-006-0143-z.CrossRefPubMed

32.

Wang L, Lee JF, Lin CY, Lee MJ. Rho GTPases mediated integrin alpha v beta 3 activation in sphingosine-1-phosphate stimulated chemotaxis of endothelial cells. Histochem Cell Biol. 2008;129(5):579–88. doi:10.1007/s00418-008-0389-8.CrossRefPubMed

33.•

Oo ML, Chang SH, Thangada S, Wu MT, Rezaul K, Blaho V, et al. Engagement of S1P(1)-degradative mechanisms leads to vascular leak in mice. J Clin Invest. 2011;121(6):2290–300. doi:10.1172/jci45403. This study used an animal model to show the role of S1PR1 in maintaining vascular permeability.CrossRefPubMedCentralPubMed

34.

Lee JF, Gordon S, Estrada R, Wang L, Siow DL, Wattenberg BW, et al. Balance of S1P1 and S1P2 signaling regulates peripheral microvascular permeability in rat cremaster muscle vasculature. Am J Physiol Heart Circ Physiol. 2009;296(1):H33–42. doi:10.1152/ajpheart.00097.2008.CrossRefPubMedCentralPubMed

35.

Sugimoto N, Takuwa N, Okamoto H, Sakurada S, Takuwa Y. Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol. 2003;23(5):1534–45.CrossRefPubMedCentralPubMed

36.

Sanchez T, Skoura A, Wu MT, Casserly B, Harrington EO, Hla T. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol. 2007;27(6):1312–8. doi:10.1161/atvbaha.107.143735.CrossRefPubMed

37.

Sikora E, Bielak-Zmijewska A, Mosieniak G. Cellular senescence in ageing. Curr Vasc Pharmacol: Age-Related Disease and Longevity; 2013.

38.

Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation. 2002;105(13):1541–4.CrossRefPubMed

39.

Minamino T, Miyauchi H, Yoshida T, Tateno K, Kunieda T, Komuro I. Vascular cell senescence and vascular aging. J Mol Cell Cardiol. 2004;36(2):175–83. doi:10.1016/j.yjmcc.2003.11.010.CrossRefPubMed

40.••

Bai B, Liang Y, Xu C, Lee MY, Xu A, Wu D, et al. Cyclin-dependent kinase 5-mediated hyperphosphorylation of sirtuin-1 contributes to the development of endothelial senescence and atherosclerosis. Circulation. 2012;126(6):729–40. doi:10.1161/circulationaha.112.118778. This study identified SIRT1 being a target of CDK5, and characterized the critical role of CDK5/SIRT1 signaling axis in endothelial senescence and atherosclerosis.CrossRefPubMed

41.

VASILE E, TOMITA Y, BROWN LF, KOCHER O, DVORAK HF. Differential expression of thymosin β-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis. FASEB J. 2001;15(2):458–66. doi:10.1096/fj.00-0051com.CrossRefPubMed

42.••

Skoura A, Michaud J, Im DS, Thangada S, Xiong Y, Smith JD, et al. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(1):81–5. doi:10.1161/atvbaha.110.213496. This study demonstrated that S1PR2 signaling in myeloid cells plays a key role in atherosclerosis.CrossRefPubMedCentralPubMed

43.

Fisher AB, Chien S, Barakat AI, Nerem RM. Endothelial cellular response to altered shear stress. Am J Physiol Lung Cell Mol Physiol. 2001;281(3):L529–33.PubMed

44.

Li Y-SJ, Haga JH, Chien S. Molecular basis of the effects of shear stress on vascular endothelial cells. J Biomech. 2005;38(10):1949–71.CrossRefPubMed

45.

Estrada R, Giridharan GA, Nguyen M-D, Roussel TJ, Shakeri M, Parichehreh V. Endothelial cell culture model for replication of physiological profiles of pressure, flow, stretch, and shear stress in vitro. Anal Chem. 2011. doi:10.1021/ac2002998. null-null.PubMed

46.

Estrada R, Giridharan G, Prabhu SD, Sethu P. Endothelial cell culture model of carotid artery atherosclerosis. Conf Proc IEEE Eng Med Biol Soc. 2011;2011:186–9.PubMed

47.

Estrada R, Giridharan GA, Nguyen M-D, Prabhu SD, Sethu P. Microfluidic endothelial cell culture model to replicate disturbed flow conditions seen in atherosclerosis susceptible regions. Biomicrofluidics. 2011;5(3):032006–11.CrossRefPubMedCentral

48.

Cantwell CA, Sterneck E, Johnson PF. Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1. Mol Cell Biol. 1998;18(4):2108–17.PubMedCentralPubMed

49.

Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev. 2014;22(3):147–51. doi:10.1097/crd.0000000000000021.CrossRefPubMed

50.

Ogura H, Arima Y, Kamimura D, Murakami M. The gateway theory: how regional neural activation creates a gateway for immune cells via an inflammation amplifier. Biomed J. 2013;36(6):269–73. doi:10.4103/2319-4170.113187.CrossRefPubMed

51.

Dessi M, Noce A, Bertucci P, di Villahermosa MS, Zenobi R, Castagnola V, et al. Atherosclerosis, dyslipidemia, and inflammation: the significant role of polyunsaturated fatty acids. ISRN Inflamm. 2013;2013:191823. doi:10.1155/2013/191823.CrossRefPubMedCentralPubMed

52.•

Muradashvili N, Khundmiri SJ, Tyagi R, Gartung A, Dean WL, Lee MJ, et al. Sphingolipids affect fibrinogen-induced caveolar transcytosis and cerebrovascular permeability. Am J Physiol Cell Physiol. 2014;307(2):C169–79. doi:10.1152/ajpcell.00305.2013. This study demonstrated a novel role of sphingolipids in fibrinogen-mediated caveolar transcytosis, leading to increase cerebrovascular permeability.CrossRefPubMed

53.

Zhang W, Mottillo EP, Zhao J, Gartung A, VanHecke GC, Lee JF, et al. Adipocyte lipolysis stimulated interleukin-6 production requires sphingosine kinase 1 activity. J Biol Chem. 2014. doi:10.1074/jbc.M114.601096. Sep 24. pii: jbc.M114.601096. [Epub ahead of print].

54.

Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis. 1985;57(1):65–73.CrossRefPubMed

55.

Wattenberg BW. Role of sphingosine kinase localization in sphingolipid signaling. World J Biol Chem. 2010;1(12):362–8. doi:10.4331/wjbc.v1.i12.362.CrossRefPubMedCentralPubMed

56.

Van Brocklyn JR, Williams JB. The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: oxidative stress and the seesaw of cell survival and death. Comp Biochem Physiol B Biochem Mol Biol. 2012;163(1):26–36. doi:10.1016/j.cbpb.2012.05.006.CrossRefPubMed

57.

Hanada K. Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochim Biophys Acta. 2003;1632(1–3):16–30.CrossRefPubMed

58.

Linn SC, Kim HS, Keane EM, Andras LM, Wang E, Merrill Jr AH. Regulation of de novo sphingolipid biosynthesis and the toxic consequences of its disruption. Biochem Soc Trans. 2001;29(Pt 6):831–5.CrossRefPubMed

59.

Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008;451(7181):904–13. doi:10.1038/nature06796.CrossRefPubMed

60.

Lipid modification—cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease—quick reference guide. National Institute for Health and Clinical Excellence May 2008, reissued March 2010.

61.

Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;1, CD004816. doi:10.1002/14651858.CD004816.pub4. Online.PubMed

62.

Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcome. 2013;6(4):390–9. doi:10.1161/circoutcomes.111.000071.CrossRef

63.

Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011;10(3):373–87. doi:10.1517/14740338.2011.540568.CrossRefPubMed

Title: Sphingosine-1-Phosphate Receptor Subtype 2 Signaling in Endothelial Senescence-Associated Functional Impairments and Inflammation
Authors: Jiawei Zhao
Dante Garcia
Allison Gartung
Menq-Jer Lee
Publication date: 01-05-2015
Publisher: Springer US
Published in: Current Atherosclerosis Reports / Issue 5/2015
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-015-0504-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2015

Nutri(meta)genetics and Cardiovascular Disease: Novel Concepts in the Interaction of Diet and Genomic Variation

Nuclear Receptors in Vascular Biology

The Promise of Proprotein Convertase Subtilisin/Kexin 9 Inhibitors for the Treatment of Familial Hypercholesterolemia

Targeting Lipoprotein (a): an Evolving Therapeutic Landscape

Translational Control Mechanisms in Angiogenesis and Vascular Biology

Novel Anti-platelet Agents in Acute Coronary Syndrome: Mechanisms of Action and Opportunities to Tailor Therapy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials